SAN FRANCISCO, May 04, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Catalyst Hedged Futures Strategy Fund (Nasdaq:HFXAX) (Nasdaq:HFXCX) (Nasdaq:HFXIX) to the recently filed securities class action pending in the United States District Court for the Eastern District of New York. The Lead Plaintiff deadline is June 27, 2017.
If you purchased or otherwise acquired Class A (HFXAX), Class C (HFXCX), or Class I (HFXIX) shares of Catalyst Hedged Futures Strategy Fund between November 1, 2014 and April 28, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://hbsslaw.com/cases/HFXAX
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
Before August 2013, Catalyst was organized as a hedge fund known as Harbor Assets, LLC. In changing to a mutual fund and raising capital from ordinary retail investors, Defendants stated that the Fund’s objective is capital appreciation and capital preservation in all market conditions, with low volatility and low correlation to the U.S. equity market.
These and other statements were allegedly materially misleading because, after the change, the Fund invested as if it were still a hedge fund and violated its stated objective. As a result, between February 2 and February 15, 2017, the Fund lost approximately 15% of its value and has continued to lose value.
On February 17, 2017, Seeking Alpha shed some light on the Fund in a report entitled, “Catalyst Hedged Futures Strategy Fund Off The Rails.” The author stated in part: (a) “[t]he problem with Catalyst’s strategy is that one of its stated objectives is capital preservation but, as we saw last week, this objective was severely violated”, (b) “[a]pparently, Catalyst’s book was set up to benefit from declines in the market”, (c) “[w]hat is now readily apparent in hindsight is that Catalyst’s book was net short gamma in way out of the money calls”, and (d) “I think it’s unfair to market this type of strategy as a ‘capital preservation strategy’ because it clearly isn’t.”
“After Catalyst changed from a hedge fund to a mutual fund it became obligated under the Investment Company Act and other securities laws to provide enhanced disclosures to ordinary retail investors,” said Hagens Berman partner Reed Kathrein. “The Fund’s apparent short strategy, if true, may contradict Defendants’ stated objectives.”
Whistleblowers: Persons with non-public information regarding Catalyst should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Google Secures Pentagon AI Deal for Classified Projects
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 



